Evidence map›Paper›PMID 39628685›Full record

ArticleInternational journal of medical sciences2024

Genetic variants of ADAM9 as potential predictors for biochemical recurrence in prostate cancer patients after receiving a radical prostatectomy.

Yung-Wei Lin, Yu-Ching Wen, Chia-Yen Lin, Chi-Hao Hsiao, Kuo-Hao Ho, Hsiang-Ching Huang, Lun-Ching Chang, Shian-Shiang Wang, Shun-Fa Yang, Ming-Hsien Chien

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Potential Influence ofInternational journal of molecular sciences · 2025
    Article
  4. Genetic variants ofInternational journal of medical sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yung-Wei LinInternational Master/PhD Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Yu-Ching WenDepartment of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Chia-Yen LinDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.
Chi-Hao HsiaoDepartment of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Kuo-Hao HoGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Hsiang-Ching HuangGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Lun-Ching ChangDepartment of Mathematical Sciences, Florida Atlantic University, Boca Raton, FL, USA.
Shian-Shiang WangDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.
Shun-Fa YangInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Ming-Hsien ChienGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) functions as a membranous bridge, forming cell-cell and cell-matrix connections that regulate tumor aggressiveness in various cancer types, including prostate cancer (PCa). Elevated ADAM9 levels in PCa were identified as a prognostic marker for biochemical recurrence (BCR) in patients who had undergone a radical prostatectomy (RP). However, impacts of genetic variants of ADAM9 on clinicopathological development and BCR remain unclear. Herein, we recruited 702 patients with PCa to evaluate associations of single-nucleotide polymorphisms (SNPs) of ADAM9 with the risk of BCR and clinicopathological development. We genotyped four loci of ADAM9 SNPs located in the promoter and intron regions using a TaqMan allelic discrimination assay, including rs10105311 (C/T), rs7006414 (T/C), rs6474526 (T/G), and rs78451751 (T/C) in 702 Taiwanese PCa patients. Our results showed that the risk of postoperative BCR was 1.508-fold higher in patients carrying the T/C genotype in ADAM9 rs7006414 compared to those with the homozygous T/T genotype, a phenomenon more pronounced in younger PCa patients (aged ≤ 65 years). Furthermore, patients with at least one polymorphic G allele in ADAM9 rs6474526 had a 2.016-fold increased risk of developing an advanced clinical primary tumor stage, particularly in a subpopulation without BCR. Clinical observations from the Genotype-Tissue Expression (GTEx) database showed increased ADAM9 expression in whole blood tissues among individuals carrying the polymorphic C allele of rs7006414 and the G allele of rs6474526. Additionally, data from The Cancer Genome Atlas indicated that elevated ADAM9 levels were observed in PCa tissues compared to corresponding matched normal tissues. Our findings suggest that the rs7006414 and rs6474526 genetic variants of ADAM9 may influence ADAM9 expression and are associated with BCR and clinicopathological development in PCa patients after an RP.

Indexed as

ADAM ProteinsMembrane ProteinsNeoplasm Recurrence, LocalPolymorphism, Single NucleotideProstatectomyProstatic NeoplasmsAgedAllelesBiomarkers, TumorGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedPrognosisTaiwanADAM9 protein, humanADAM ProteinsBiomarkers, TumorMembrane ProteinsA disintegrin and metalloprotease 9Biochemical recurrenceClinicopathologic progressionProstate cancerSingle-nucleotide polymorphism

Identifiers

PMID39628685
PMCPMC11610326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.